Traditional Tissue Biopsies Are Not Providing the Type of Real-Time Monitoring Necessary for Effectively Catching Relapse
As molecular diagnostics for oncology shifts into clinical practice, efforts have not only focused on genotyping patient-specific tumors to initiate targeted therapies, but on early detection, availability, improved quality control, and refined workflow.
One major push, that exemplifies the concomitance of these trends, has been the rise of the less-invasive and more cost-effective liquid sampling for cancer diagnosis; sometimes called a liquid biopsy.
Read more: Rising Liquid Biopsy Tide Lifts Cancer Dx
 |
| The FDA recently approved Hologic’s prostate cancer test, which improves upon the less sensitive and less specific standard PSA tests via examination of the PCA3 gene in urine. |
Source: genengnews
